title: Response to Letter to the Editor regarding: Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.
authors.affiliation: University of Louisville, Louisville, KY, USA. Electronic address: k0brya01@louisville.edu.
authors.forename: Kristina
authors.initials: K
authors.lastname: Bryant
authors.affiliation: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
authors.forename: Robert W
authors.initials: RW
authors.lastname: Frenck
mesh_terms: D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000276:immunology; D022242:Pneumococcal Vaccines / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000276:immunology*; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate